Traws Pharma, Inc. 8-K

What Happened
Traws Pharma, Inc. (TRAW) announced on April 15, 2026 that it priced a private placement offering of 5,982,919 shares of common stock (or, in lieu, pre-funded warrants), plus Series A, B and C warrants. The offering will raise approximately $10,000,000 (before placement agent fees/expenses) at a per-unit price of $1.6730 (or $1.6630 for units including a pre-funded warrant). If all issued Series A, B and C warrants are exercised for cash, the company could receive additional gross proceeds of about $50,000,000. The offering is being conducted at-the-market under Nasdaq rules and is expected to close on or about April 16, 2026, subject to customary closing conditions.

Key Details

• Securities issued: 5,982,919 Purchased Shares (or pre-funded warrants) and initial rights to purchase up to 5,982,919 shares each under Series A and Series B Warrants, and up to 17,948,757 shares under Series C Warrants.
• Pricing: $1.6730 per Purchased Share + accompanying warrants; $1.6630 per Pre-Funded Warrant + accompanying warrants; Pre-Funded Warrants exercisable immediately at $0.01 per share. Series warrants exercise price: $1.673 (subject to adjustment).
• Use of proceeds: advance the company’s influenza program through a Phase 2a human challenge trial in the U.K.
• Placement agents & fees: Cantor Fitzgerald (lead), Citizens JMP and Tungsten Advisors (via Finalis) — cash fee of 6.0% of gross proceeds; up to $175,000 reimbursement to Cantor.
• Shareholder approval & registration: the company must call shareholder meetings to obtain specified Shareholder Approval for certain warrant exercises and is required to file a resale registration statement within 30 days of closing (Form S-3 or S-1) or pay liquidated damages if deadlines are missed.
• Exercise limits & anti-dilution: holder exercises limited to 4.99% (or opt-in 9.99%) ownership post-exercise; holders may receive pre-funded warrants instead if limited. Warrants adjust for certain corporate events and do not carry voting rights.

Why It Matters
This financing provides immediate capital (~$10M) to fund Traws Pharma’s next clinical step for its influenza program, while offering the company potential future funding (up to ~$50M) if investors exercise the warrants. For shareholders, the transaction dilutes existing equity when shares are issued/exercised and includes investor protections (registration rights, shareholder approval conditions). Investors should note the resale registration timeline, exercise restrictions, and that the securities were sold in a private placement (unregistered under the Securities Act).